GSA Capital Partners LLP Purchases 151,613 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

GSA Capital Partners LLP increased its position in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 432.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 186,650 shares of the company’s stock after purchasing an additional 151,613 shares during the quarter. GSA Capital Partners LLP owned approximately 0.40% of Cardiff Oncology worth $498,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. boosted its position in Cardiff Oncology by 380.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock valued at $2,699,000 after acquiring an additional 962,940 shares in the last quarter. Blair William & Co. IL boosted its position in Cardiff Oncology by 32.4% during the 1st quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after acquiring an additional 42,180 shares in the last quarter. Vanguard Group Inc. boosted its position in Cardiff Oncology by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock valued at $10,260,000 after acquiring an additional 9,468 shares in the last quarter. Point72 DIFC Ltd bought a new stake in Cardiff Oncology during the 2nd quarter valued at $27,000. Finally, Rhumbline Advisers bought a new stake in Cardiff Oncology during the 2nd quarter valued at $102,000. Institutional investors own 16.29% of the company’s stock.

Analysts Set New Price Targets

CRDF has been the subject of several analyst reports. HC Wainwright decreased their price objective on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, November 8th. Craig Hallum initiated coverage on Cardiff Oncology in a report on Friday, September 6th. They set a “buy” rating and a $8.00 price objective for the company.

Cardiff Oncology Price Performance

Shares of CRDF stock opened at $2.62 on Wednesday. The firm has a market capitalization of $133.96 million, a price-to-earnings ratio of -2.79 and a beta of 1.93. The business has a fifty day moving average of $2.83 and a 200 day moving average of $2.70. Cardiff Oncology, Inc. has a 1 year low of $1.12 and a 1 year high of $6.42.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.